ARA-290 16 mg – Injectable Peptide for Pain Relief

Subtotal	$0.00
Shipping	$0.00
Total	$0.00

ARA-290 - Peptide Sciences USA Research Peptides

Active Substance: ARA290
Concentration: 16 mg per vial
Pack Size: Single vial (lyophilized powder)
Manufacturer: Peptide Sciences USA
Brand Name: ARA-290
Molecular Formula: C₅₁H₈₄N₁₆O₂₁
Molecular Weight: 1257 Da
Sequence: Pyroglu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Synonyms: Cibinetide, Pyroglutamate Helix B Surface Peptide

Manufacturer	Peptide Sciences USA
Brand	ARA-290
Substance	ARA290
Concentration	16 mg
Pack Size	vial

Out of Stock

Research Peptides Description

ARA-290 16 mg – Advance Neuropathic Pain and Tissue Repair Research

Product Summary

Imagine a research breakthrough that alleviates neuropathic pain, promotes tissue repair, and reduces inflammation. ARA-290 16 mg vial from Peptide Sciences USA, a non-hematopoietic peptide derived from erythropoietin, delivers these possibilities. By targeting the innate repair receptor, ARA-290 offers a powerful tool for exploring solutions to chronic pain, nerve damage, and metabolic health challenges.

How ARA-290 Works

ARA-290, also known as Cibinetide, is an 11-amino-acid peptide (sequence: Pyroglu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) engineered from the helix B domain of erythropoietin (EPO). Unlike EPO, ARA-290 does not stimulate red blood cell production, instead selectively activating the innate repair receptor (IRR), a heteromer of the EPO receptor and β-common receptor. This interaction inhibits proinflammatory cytokine production (e.g., TNF-α) and promotes tissue repair by stimulating nerve fiber regrowth and reducing inflammation. ARA-290 also inhibits TRPV1 channel activity, a key modulator of pain sensation, providing analgesic effects.

In preclinical studies, ARA-290 reduced mechanical allodynia in nerve injury models and increased corneal nerve fiber density in sarcoidosis patients . Clinical trials showed a 50% improvement in neuropathic symptoms in sarcoidosis and type 2 diabetes patients after 28 days of 4 mg daily subcutaneous injections, alongside improved HbA1c and lipid profiles . Its short plasma half-life (~2 minutes) ensures targeted action without systemic side effects, making it ideal for researching neuropathic pain, diabetes, and tissue repair.

Why Choose ARA-290?

ARA-290 stands out as a transformative peptide for research into pain relief and tissue repair. Here's why it's exceptional:

Neuropathic Pain Relief: Reduces allodynia and hyperalgesia by up to 50% in 28 days by targeting TRPV1 channels and inflammation.
Tissue Repair: Promotes nerve fiber regrowth, increasing corneal nerve density in sarcoidosis and diabetes models .
Metabolic Support: Improves HbA1c and lipid profiles in type 2 diabetes, supporting metabolic health research.
Anti-Inflammatory Action: Inhibits proinflammatory cytokines, reducing systemic inflammation for conditions like sarcoidosis and lupus .
High Purity: Peptide Sciences USA ensures 99% purity through advanced synthesis, guaranteeing reliable research outcomes.

ARA-290 16 mg empowers researchers to explore innovative solutions for chronic pain, nerve regeneration, and immune modulation, backed by robust preclinical and clinical data.

Product Specifications

Peptide Sciences USA's ARA-290 16 mg vial is designed for precision in neuropathic pain and tissue repair research, offering unmatched quality. Here's the breakdown:

Composition: Contains 16 mg of ARA-290 (C₅₁H₈₄N₁₆O₂₁, molecular weight 1257 Da), an 11-amino-acid peptide.
Pack Size: Single vial of lyophilized powder, requiring reconstitution for subcutaneous injection.
Manufacturing: Produced by Peptide Sciences USA with 99% purity, verified by High-Performance Liquid Chromatography and Mass Spectrometry.
Usage Guidelines: Reconstitute with bacteriostatic water and administer subcutaneously, typically at 2–4 mg daily for 28 days in research protocols. Use under professional supervision.
Storage: Store lyophilized powder at -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.
Safety: No significant safety issues reported in clinical trials; mild injection site reactions possible. Long-term human data is limited, requiring research oversight.

This peptide is for research purposes only, offering a reliable platform for studying pain relief and tissue regeneration.

Legal Disclaimer

ARA-290 16 mg is supplied for research purposes only and is not FDA-approved for human use, though it has orphan drug status for sarcoidosis-associated neuropathy. It is not intended to diagnose, treat, cure, or prevent any condition. Consult a licensed professional before use. Peptide Sciences USA assumes no liability for misuse. All information is educational and based on preclinical and clinical research.

Frequently Asked Questions

What is ARA-290 used for?

ARA-290 is used in research to explore neuropathic pain relief, tissue repair, and immune modulation. It targets the innate repair receptor to reduce inflammation and promote nerve regeneration in conditions like sarcoidosis, diabetes, and neuropathy.

What are the benefits of ARA peptide?

ARA-290 reduces neuropathic pain by up to 50%, promotes corneal nerve fiber regrowth, improves metabolic control (e.g., HbA1c in diabetes), and modulates inflammation, making it valuable for researching sarcoidosis, diabetes, and tissue repair.

How long does it take ARA-290 to work?

In clinical trials, ARA-290 showed neuropathic symptom improvement within 28 days of daily 4 mg subcutaneous injections, with effects sustained for at least 28 days post-treatment. Preclinical studies noted pain relief within days.

Is ARA-290 FDA approved?

ARA-290 is not FDA-approved for human use but has orphan drug status for sarcoidosis-associated neuropathic pain. It is in phase III trials for neuropathy and other applications, pending further regulatory review.

What are the potential side effects of ARA-290?

Clinical trials report no significant safety issues, with mild injection site reactions possible. Long-term human safety data is limited, requiring professional oversight for research use.